Research programme: influenza therapy - Imperial College/Xenova
Alternative Names: OX40:Ig; OX40L-IgGLatest Information Update: 01 Nov 2011
At a glance
- Originator Imperial College of Science, Technology and Medicine; Xenova Group
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 18 Apr 2006 No development reported - Preclinical for Influenza virus infections in United Kingdom (unspecified route)
- 24 Oct 2003 Preclinical trials in Influenza virus infections in United Kingdom (unspecified route)